This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leier, C. V. Articles by Unverferth, D. V. Search for Related Content PubMed PubMed Citation Articles by Leier, C. V. Articles by Unverferth, D. V. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB ISOSORBIDE DINITRATE

Circulation, Vol 67, 817-822, Copyright © 1983 by American Heart Association

ARTICLES

Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure

CV Leier, P Huss, RD Magorien and DV Unverferth

We studied 30 patients with moderate-to-severe congestive heart failure in a double-blind, randomized, placebo-controlled trial to determine the acute and long-term effects of isosorbide dinitrate on clinical status and on resting and exercise hemodynamics. Seventeen patients received placebo and 13 isosorbide dinitrate. First-dose isosorbide dinitrate (40 mg orally) decreased resting and exercise pulmonary capillary wedge pressure, pulmonic and systemic arterial pressures and pulmonic and systemic vascular resistances without augmenting exercise capacity. Compared with placebo, chronic therapy with isosorbide dinitrate (40 mg orally every 6 hours for 12 weeks) significantly improved clinical status and exercise capacity. Resting and exercise systemic blood pressure and systemic vascular resistance returned to baseline values during chronic isosorbide dinitrate therapy, but pulmonary capillary wedge pressure, pulmonary artery pressure and pulmonary vascular resistance remained improved. In patients with congestive heart failure, 12 weeks of oral isosorbide dinitrate therapy improves resting and exercise hemodynamics, exercise capacity, and clinical status; tolerance develops to the systemic arterial vascular effects without attenuation of the venous and pulmonary vascular effects.

This article has been cited by other articles:

				U. Elkayam, J. V. Johnson, A. Shotan, S. Bokhari, A. Solodky, M. Canetti, O. R. Wani, and I. S. Karaalp Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Organic Nitrates in Patients With Chronic Heart Failure Treated With Angiotensin-Converting Enzyme Inhibition Circulation, May 25, 1999; 99(20): 2652 - 2657. [Abstract] [Full Text] [PDF]

				W. T. Abraham Pharmacologic Management of Chronic Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190. [Abstract] [PDF]

				A. E. Steimle, L. W. Stevenson, C. Chelimsky-Fallick, G. C. Fonarow, M. A. Hamilton, J. D. Moriguchi, A. Kartashov, and J. H. Tillisch Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure Circulation, August 19, 1997; 96(4): 1165 - 1172. [Abstract] [Full Text]

				J. D. Parker, A. B. Parker, B. Farrell, and J. O. Parker The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 866 - 875. [Abstract] [Full Text]

				J. N. Cohn The Management of Chronic Heart Failure N. Engl. J. Med., August 15, 1996; 335(7): 490 - 498. [Full Text] [PDF]

				S. Puri, B. L. Baker, D. P. Dutka, C. M. Oakley, J. M. B. Hughes, and J. G. F. Cleland Reduced Alveolar–Capillary Membrane Diffusing Capacity in Chronic Heart Failure : Its Pathophysiological Relevance and Relationship to Exercise Performance Circulation, June 1, 1995; 91(11): 2769 - 2774. [Abstract] [Full Text]

				A. M. Feldman Can We Alter Survival in Patients With Congestive Heart Failure? JAMA, April 8, 1992; 267(14): 1956 - 1961. [Abstract] [PDF]

				J. Myers and V. F. Froelicher Hemodynamic Determinants of Exercise Capacity in Chronic Heart Failure Ann Intern Med, September 1, 1991; 115(5): 377 - 386. [Abstract] [PDF]

				U. Elkayam Tolerance to Organic Nitrates: Evidence, Mechanisms, Clinical Relevance, and Strategies for Prevention Ann Intern Med, April 15, 1991; 114(8): 667 - 677. [Abstract] [PDF]

				M. Packer Clinical Trials in Congestive Heart Failure: Why Do Studies Report Conflicting Results? Ann Intern Med, July 1, 1988; 109(1): 3 - 5. [Abstract] [PDF]

				P. R. Marantz, M. H. Alderman, and J. N. Tobin Diagnostic Heterogeneity in Clinical Trials for Congestive Heart Failure Ann Intern Med, July 1, 1988; 109(1): 55 - 61. [Abstract] [PDF]

				C. D. Mulrow, J. P. Mulrow, W. D. Linn, C. Aguilar, and G. Ramirez Relative Efficacy of Vasodilator Therapy in Chronic Congestive Heart Failure: Implications of Randomized Trials JAMA, June 17, 1988; 259(23): 3422 - 3426. [Abstract] [PDF]

				J. Abrams A Reappraisal of Nitrate Therapy JAMA, January 15, 1988; 259(3): 396 - 401. [Abstract] [PDF]

				T. D. Giles, M. G. Thomas, A. C. Quiroz, J. C. Rice, W. Plauche, and G. E. Sander Acute and Short-Term Effects of Clonidine in Heart Failure Angiology, July 1, 1987; 38(7): 537 - 548. [Abstract] [PDF]

				M. Szycher Recent Advances in Transdermal Delivery Systems J Biomater Appl, January 1, 1986; 1(2): 207 - 238. [PDF]

				J. Abrams Vasodilator Therapy for Chronic Congestive Heart Failure JAMA, December 6, 1985; 254(21): 3070 - 3074. [Abstract] [PDF]